Israel Medical Innovation - Israeli-South African Trade, Technology ...

Israel Medical Innovation2011
BSP Biological Signal Processing
www.bspmedical.com
Category:
Diagnostics
Cardiovascular and
Peripheral Vascular
Company Status:
Initial Revenues
Company at a Glance
Founded in 2000, BSP Biological Signal Processing Ltd. is a medical device company with
corporate offices in Tel Aviv, Israel and a US subsidiary – BSP Inc. in Boston, MA. BSP is
publicly traded on the Tel Aviv Stock Exchange since 2006 (TASE:BSP).
BSP develops and commercializes a new generation of systems for non invasive diagnosis
and monitoring of Coronary Artery Disease (CAD), based on advanced signal processing of
the ECG signal which integrates the Company’s unique, patented, HyperQ technology.
Technology and Product(s)
BSP has pioneered the clinical implementation of high-frequency ECG and has developed
it into a fast, accurate, low-cost, simple to operate and non-radiating technology for
detecting CAD with greater clinical value than the current standard ECG. The company’s
proprietary HyperQ technology extracts and analyses the high-frequency components
of the ECG and provides a unique diagnostic index. Thousands of patients have been
tested with the HyperQ system to date, demonstrating consistently that HyperQ is far
superior to conventional ECG both in sensitivity and specificity, with the potential to
save up to 50% of the unnecessary radioactive imaging procedures, while improving the
standard of care. BSP’s Intellectual Property portfolio is backed by four granted patents
and 14 filed applications in different stages.
HyperQ EX-300: The world’s first advanced system incorporating conventional stress ECG
and the revolutionary highly accurate HyperQ CAD diagnosis in a single, small footprint
unit. This system is FDA (510k) cleared and CE marked.
HyperQ AD-100: Seamlessly integrating the highly accurate HyperQ CAD diagnosis into
the existing workflow, HyperQ AD-100 is an “add-on” to standard stress ECG systems,
enhancing conventional ECG results. This system is FDA (510k) cleared and CE marked.
Goal
Objectives: The Company’s primary strategic objectives include establishing HyperQ as
the first line modality for monitoring and diagnosis of CAD in cardiology clinics, ambulatory
and hospital settings and attaining reimbursement code and premium coverage over
competitors for the HyperQ diagnostic modality in the US. Growth in market penetration
and market share will be achieved through a combination of business partnerships
with equipment and healthcare service providers, and by the establishment of a global
marketing and sales presence.
Target Businesses: Distributors specializing in cardiovascular diagnostic devices, leading
manufacturers in the field of cardiovascular diagnostic devices for potential business
partnerships, leading health service providers.
Target Countries: Worldwide
Schedule a Meeting at
Return to Table of Content
21